(Q44584072)

4 December 2017

0 references

Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials (English)

1 reference

4 December 2017

1 reference

1 reference

3

Sun Ha Jee

1 reference

4 December 2017

Su Hyun Kim

1

1 reference

PubMed ID

12972682

4 December 2017

Young Mee Lee

series ordinal

2

1 reference

PubMed ID

12972682

4 December 2017

Chung Mo Nam

series ordinal

4

1 reference

4 December 2017

1 September 2003

1 reference

4 December 2017

1 reference

4 December 2017

11

1 reference

4 December 2017

9

1 reference

4 December 2017

1116-1123

1 reference

Prevalence and Trends in Obesity Among US Adults, 1999-2000

4 December 2017

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.152

Medical hazards of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.152

Sibutramine. A review of its contribution to the management of obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.152

The discovery and status of sibutramine as an anti-obesity drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.152

Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.152

Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.152

Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.152

Sibutramine produces dose-related weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.152

Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.152

Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.152

Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.152

Effects of sibutramine on the treatment of obesity in patients with arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.152

Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.152

Current methods of the US Preventive Services Task Force: a review of the process

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.152

Effects of sibutramine on resting metabolic rate and weight loss in overweight women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.152

Sibutramine in weight control: a dose-ranging, efficacy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.152

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.152

The file drawer problem and tolerance for null results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.152

Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.152

Long-term weight loss with sibutramine: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.152

Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.152

Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.152

The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.152

Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.152

Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.152

Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.152

Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.152

Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.152

A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.152

The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.152

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/OBY.2003.152

1 reference

4 December 2017

1 reference

PubMed ID

12972682